In July 2009, Teva Pharmaceuticals released Plan B One-Step, containing 1.5 mg levonorgestrel, which is now available OTC for patients 17 years of age and older and as prescription for girls younger than 17. 1 On August 13, 2010, HRA Pharma obtained approval for the use of ulipristal acetate (ella) 30-mg tablets for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. As ulipristal acetate was unavailable in any drug product in the US, it obtained approval as a new molecular entity. Ella potentially extends the availability of FDA-approved EC from 3 days (72 hours) after unprotected intercourse for currently approved levonorgestrel-based EC products to 5 days (120 hours). Under the proprietary name of ellaOne, ulipristal gained approval from the European Medicines Agency (EMA) in May 2009 and is currently marketed in over 20 countries. 6
Data Sources and Selection
Relevant articles were identified and reviewed through searches of PubMed (1994-March 2011) and clinicaltrials. gov, using the key terms ulipristal and CDB-2914. Ella approval documents were obtained and reviewed from Drugs@FDA on the FDA Web site.
Pharmacology and Pharmacokinetics
Ulipristal acetate is a selective progesterone receptor modulator with both antagonistic and partial agonistic effects. 7 It binds the human progesterone receptor and prevents progesterone from occupying the receptor. Although no single mechanism of action has been established for EC, the action of levonorgestrel as an EC appears to be similar to that of ulipristal acetate in that it is thought to inhibit ovulation and fertilization. Alteration of the endometrium to inhibit implantation is a potential mechanism, but the changes may not be sufficient to prevent implantation. 8 Ulipristal acetate is indicated to be taken within 120 hours (5 days) of unprotected intercourse, whereas levonorgestrel is indicated within 72 hours (3 days), but has been shown to be effective when the first dose is taken up to 5 days after intercourse Both agents are thought to be effective only before pregnancy is established. Ulipristal acetate demonstrates structural similarity to mifepristone in that both are 19-norprogesterone derivatives with 11β-aryl substitutions ( Figure 1 ). 9 Mifepristone was the first progesterone receptor antagonist and has been in clinical use for over 25 years. It is used as a single dose for the termination of pregnancy. 10 The pharmacodynamics associated with ulipristal acetate depend upon the timing of its administration in the menstrual cycle. 7 Upon administration of ulipristal acetate during the midfollicular phase, inhibition of folliculogenesis and reduction of estradiol concentration occur. When administering ulipristal acetate at the time of the luteinizing hormone (LH) peak, follicular rupture is delayed by 5-9 days. Endometrial maturation is not significantly delayed upon dosing of ulipristal acetate in the early luteal phase, but endometrial thickness decreases by 0.6 ± 2.2 mm.
Ulipristal acetate demonstrates high binding (>94%) to plasma proteins, including high-density lipoprotein, α-acid glycoprotein, and nonesterified fatty acid. It undergoes metabolism to mono-demethylated and di-demethylated metabolites, with the mono-demethylated metabolite being pharmacologically active. 6 Although no drug interaction studies have been conducted in vivo for ulipristal acetate, in vitro data indicate that it is predominantly metabolized by CYP3A4. 7 Therefore, drugs or herbal products that induce the CYP3A4 isoenzyme (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxacarbazepine, phenytoin, rifampin, St. John's wort, and topiramate) may decrease concentrations and the effectiveness of ulipristal acetate. Plasma concentrations of ulipristal acetate may be increased by medications such as itraconazole or ketoconazole, which are CYP3A4 inhibitors. 7 In vitro data demonstrate that ulipristal acetate neither induces nor inhibits the activity of CYP450 enzymes.
Food increases the extent of absorption of ulipristal acetate and its mono-demethylated metabolite as indicated by a 20-25% higher area under the curve compared to fasting conditions. However, Phase 3 studies were conducted without restriction for food, so ulipristal acetate can be administered to patients regardless of a meal. To our knowledge, no studies for ulipristal acetate have been conducted in patients with hepatic or renal dysfunction to date. 6 Further pharmacologic and pharmacokinetic parameters are described in Table 1 . Phase 2/3 extension study comparing 2 doses of ulipristal acetate (10 mg and 50 mg) has not yet been published. An unmicronized 50-mg gelatin capsule was chosen for the Phase 2/3 studies based on results from previous pharmacodynamic studies; however, commercialization of this formulation was not viable. 11 Based on the results of a pharmacokinetic bridging study with 3 different formulations and an indirect pharmacokinetic comparison with data on the absorption of the 50-mg capsule, a 30-mg tablet was chosen to be evaluated in the pivotal Phase 3 registration trials. 11 Information pertaining to the published clinical trials is described in detail below.
Clinical Trials
Creinin et al. 12 conducted a Phase 2/3 randomized, double-blind, noninferiority trial to evaluate the safety and efficacy of ulipristal acetate (single dose of 50 mg) compared to levonorgestrel (2 doses of 0.75 mg taken 12 hours apart) within 72 hours of unprotected intercourse. The study was initiated before data demonstrating the efficacy of levonorgestrel as a single-dose regimen and beyond 72 hours from sexual intercourse were available. The study was performed in 1672 healthy women, at least 18 years of age, seeking EC within 72 hours of unprotected intercourse or contraceptive failure. Women pregnant at screening or enrollment were excluded from the study. The primary outcome of pregnancy was established via a positive highsensitivity urine pregnancy test at follow-up (5-7 days after the expected onset of the next menstrual period), and confirmed by quantitative serum β-human chorionic gonadotropin (hCG). The study was designed as a noninferiority trial to test the hypothesis that ulipristal acetate has a pregnancy rate no greater than that of levonorgestrel with a noninferiority margin of 2%. Daily diaries were used from the time of study drug administration through the next menses to record adverse effects and sexual activity. Study participants were primarily young (mean age 24.3 years), white, single women. As illustrated in Table 2 , 7 pregnancies occurred in the ulipristal acetate group (n = 775; 0.9%; 95% CI 0.2 to 1.6) and 13 in the levonorgestrel group (n = 774; 1.7%; 95% CI 0.8 to 2.6) in the efficacy evaluable population. This population did not include those lost to follow-up, 5 women with pretreatment pregnancy, and 24 women who used additional EC during the treatment cycle. The difference in number of pregnancies between treatment groups was statistically noninferior (p < 0.001). Based on the estimated cycle day of unprotected intercourse, 85% and 69% of anticipated pregnancies were averted. 12 Efficacy was also evaluated in the modified intent-to-treat population (mITT) population, which included all women who were randomized and for whom a pregnancy outcome was known. In the mITT population, 12 pregnancies were observed among ulipristal acetate users (n = 792; 1.5%; 95% CI 0.7 to 2.4), and 14 among levonorgestrel users (n = 786; 1.8%; 95% CI 0.9 to 2.7%), also a statistically noninferior difference (p = 0.003).
Fine et al. 13 conducted a Phase 3, prospective, open-label study to evaluate the safety and efficacy of a single dose of ulipristal acetate 30 mg in women at least 18 years of age presenting to Planned Parenthood clinics 48-120 hours after unprotected intercourse. Exclusion criteria included pregnancy, breastfeeding, intrauterine devices, tubal ligation, or partner vasectomy, and uncertainty about recent menstrual history. Daily diaries were used and pregnancy status was determined via a high-sensitivity urinary hCG test and return of menses. Up to 3 visits were scheduled during the study, beginning with an initiation visit during which a high-sensitivity urine pregnancy test was performed and a blood sample was obtained. The first followup visit was conducted 5-7 days after expected onset of menses and included a second pregnancy test. A second follow-up visit occurred only if the previous pregnancy test result was positive or if the test result was negative but menses had not occurred. Subjects were mostly healthy, young (mean age 24.4 years), white, healthy weight to overweight women. The primary efficacy endpoint of pregnancy rate was evaluated in the mITT population, which excluded women lost to follow-up and those 36 years of age and older. When taken 48-120 hours after unprotected intercourse, ulipristal acetate administration resulted in a statistically significant reduction in the pregnancy rate, from an expected rate of 5.5% 15 to an observed rate of 2.2%. While the efficacy of ulipristal acetate did not appear to decrease, the sample sizes for the individual time intervals of 72-96 and 96-120 hours were not large enough to determine statistical significance.
In a Phase 3 randomized, single-blind, multicenter noninferiority trial, Glasier et al. 14 breastfeeding, sterilized (or their partner was sterilized), fitted with an intrauterine device, or taking hormonal contraception. Daily diaries were used to record sexual intercourse, contraceptive use, vaginal bleeding, concomitant medication, and adverse events. Follow-up was conducted 5-7 days after expected menses. The primary efficacy endpoint was the pregnancy rate in women who received EC within 72 hours of unprotected intercourse. The rate of pregnancy in women who received EC within 120 hours was analyzed as a secondary endpoint. This study was not powered to demonstrate superiority. Participants were primarily young (mean age 24.5 years in the ulipristal acetate group and 24.9 years in the levonorgestrel group), healthy, white women. The efficacy-evaluable population, which excluded women lost to follow-up, those over 35 years, women with unknown follow-up pregnancy status, and those who had reenrolled in the study, included 1696 women who received EC within 72 hours of sexual intercourse (ulipristal acetate, n = 844; levonorgestrel, n = 852). A total of 15 pregnancies in the ulipristal acetate (1.8%; 95% CI 1.0 to 3.0) and 22 in the levonorgestrel group (2.6%; 95% CI 0.35 to 1.31) were observed in this population. Significantly more pregnancies were prevented in the ulipristal acetate group than in the levonorgestrel group in women who received EC between 72 and 120 hours after sexual intercourse (p = 0.037). 12 Fifty pregnancies occurred in the ulipristal acetate group and 30 in the levonorgestrel group in the ITT population. Glasier et al. 14 also conducted a meta-analysis of the combined data from the efficacy evaluable populations in their trial and the Creinin et al. trial. 12 The rate of pregnancy was significantly lower in the ulipristal acetate group compared to the levonorgestrel group when EC was taken within 24 hours (OR 0.35; 95% CI 0.11 to 0.93), 72 hours (OR 0.58; 95% CI 0.33 to 0.99), or 120 hours (OR 0.55; 95% CI 0.32 to 0.93) after sexual intercourse (p < 0.05 for all). The validity of these data is questionable as the metaanalysis included only 2 trials, both with noninferiority designs and different dosing/formulations and populations.
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Adverse Effects
Seven serious adverse events (SAEs) were observed in the Phase 2/3 and Phase 3 trials. 11- 14 With the exception of a report of dizziness in the Glasier et al. trial, which was identified as "possibly related," all other SAEs were determined by the investigator to be unrelated to ulipristal acetate use. 11 In a pooled ITT population including subjects receiving ulipristal acetate in the 3 published trials, 12-14 the most commonly reported adverse events (Table 3 ) included headache (17%; n = 3412), breast tenderness (16%; n = 775), nausea (14.9%; n = 3412), and abdominal pain (12.8%; n = 3412). Those most common in subjects who received levonorgestrel were headache (23%; n = 1891), abdominal pain (17.5%; n = 1891), fatigue (17.5%; n = 1891), and nausea (16.5%; n = 1891). Alterations in menses onset were also reported, as subjects in the pooled Phase 3 population who did not become pregnant reported a mean change of 2.5 days (9.4 SD) in average cycle length. 11
Dosage and Formulary Considerations
The licensed dose of ella consists of 1 tablet of ulipristal acetate 30 mg, taken as soon as possible, within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure. 7 The drug must be obtained via prescription and can be administered at any point during the menstrual cycle, without regard to meals. If vomiting occurs within 3 hours after the dose, it should be repeated. Pregnancy should be excluded prior to its administration.
Currently, women with state-funded health insurance for EC services require a prescription for levonorgestrel or similar products for coverage by Medicaid. 2 Plan B One-
Step and Next Choice are available as OTC products and, as such, are not covered by private insurance for women aged 18 years and older. Because ulipristal acetate is available only through prescription, the time and money for a physician's appointment, as well as the time and transportation required to travel to the office or clinic, present potential hurdles to it being widely used as EC. 2 Another pricing consideration associated with ulipristal acetate is the cost of the pregnancy test required prior to administration of the drug. However, depending upon the individual's insurance plan, ulipristal acetate may be covered, unlike Plan B One-Step and Next Choice. 2 For women without insurance, ulipristal acetate can be obtained via an online prescription and shipped for next-day delivery with an approximate cost of $77. 16 Plan B One-Step and Next Choice can be obtained OTC at a local pharmacy by women 17 years of age and older and as prescription for girls younger than 17 for prices ranging from $35 to $60, depending on the pharmacy.
Summary
Based on results of the clinical trials summarized here, ulipristal acetate administration resulted in a statistically significant reduction in pregnancy rate after unprotected intercourse and prevented a significantly larger number of pregnancies than levonorgestrel when taken up to 120 hours after unprotected intercourse. Commonly reported adverse effects associated with ulipristal acetate in these trials included headache, breast tenderness, nausea, and abdominal pain. As ulipristal acetate demonstrates structural similarity to mifepristone, which when administered in a single dose terminates pregnancy, much debate regarding the potential mechanism of action of ulipristal acetate continues to occur among various parties, primarily on the basis of ethical and religious concerns. This controversy also stems from the fact that the primary mechanism of action of ulipristal acetate has not been clearly defined, as well as the fact that pregnancy must be excluded prior to its administration. As a result of these factors, certain groups could make the argument that ulipristal acetate could be used to terminate pregnancy. However, while the drug has been shown to be effective in preventing pregnancy during the 5 days (120 hours) between unprotected intercourse and implantation of a fertilized egg, it is thought to be ineffective after implantation of a fertilized egg and therefore presents no increased risk to an established pregnancy or harm to a developing embryo. 8 Acetato de Ulipristal para Anticoncepción de Emergencia SE Snow, SN Melillo, y CI Jarvis Ann Pharmacother 2011;45:780-6. EXTRACTO OBJETIVO: Revisar la farmacología, farmacocinética, eficacia y seguridad de los datos sobre acetato de ulipristal, un nuevo anticonceptivo de emergencia aprobado para uso hasta en 120 horas. 
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SELECCIÓN DE ESTUDIOS Y EXTRACCIÓN DE DATOS:
Todos los datos publicados y documentos de aprobación de FDA que examinan estudios farmacológicos, farmacocinéticos y clínicos relacionados con acetato de ulipristal como un anticonceptivo de emergencia fueron evaluados. Los estudios seleccionados incluyeron tres (3) ensayos aleatorios y un (1) meta-análisis de acetato de ulipristal.
SÍNTESIS DE DATOS:
Acetato de ulipristal es un anticonceptivo de emergencia agonista/antagonista de progesterona aprobado para la prevención de embarazo para ser tomado lo antes posible dentro de 120 horas luego de relaciones sexuales no protegidas o falla conocida o sospechada del anticonceptivo. Según resultados de ensayos clínicos fase 3 usados para obtener aprobación, la administración de acetato de ulipristal fue por lo menos tan efectiva como la de levonorgestrel en la reducción de la tasa de embarazo cuando se estudia sola luego de relaciones sexuales no protegidas y cuando se toma hasta dentro de 120 horas luego de relaciones sexuales no protegidas. Los efectos adversos asociados con acetato de ulipristal reportados comúnmente en los ensayos incluyeron dolor de cabeza, sensibilidad de los senos, náusea y dolor abdominal. CONCLUSIONES: El acetato de ulipristal es efectivo como anticonceptivo de emergencia por hasta 120 horas luego de relaciones sexuales no protegidas. Como ulipristal está disponible solamente mediante receta, puede ser cubierto por el seguro de la mujer. No obstante, los factores adicionales de gastos de viaje y tiempo para hacer y asistir a citas médicas deben tomarse en cuenta al considerar el uso de ulipristal como un anticonceptivo de emergencia. Debido a la similaridad de su 
SÉLECTION DES DONNÉES:
Toutes les données publiées portant sur la pharmacologie, la pharmacocinétique et les études cliniques de l'acétate d'ulipristal en contraception d'urgence, de même que le résumé de la FDA ont été évalués. Trois études à répartition aléatoire et une métaanalyse ont été sélectionnées. RÉSUMÉ: L'acétate d'ulipristal est un agoniste/antagoniste de la progestérone approuvé pour prévenir une grossesse en situation d'urgence. Il doit être administré dès que possible et jusqu'à 120 heures après un rapport sexuel non protégé ou un échec connu ou suspecté de contraception. D'après les résultats d'une étude pivot de phase 3, l'administration d'acétate d'ulipristal est au moins aussi efficace que le levonorgestrel pour prévenir la grossesse en situation d'urgence. Les effets secondaires les plus fréquemment rapportés incluaient maux de tête, sensibilité aux seins, nausées, et douleurs abdominales.
CONCLUSIONS: L'acétate d'ulipristal est efficace en contraception d'urgence jusqu'à 120 heures après un rapport sexuel non protégé. L'utilisation de l'ulipristal requiert une prescription du médecin. Le temps, les coûts et le délai associés à la nécessité de voir un médecin doivent être pris en considération lors de son utilisation comme contraceptif d'urgence. De plus, comme sa structure chimique est similaire à celle de la mifepristone, une certaine controverse existe.
Traduit par Suzanne Laplante
